Title:
【発明の名称】薬剤供給システムとしての機能的活性融合ペプチドを含む人工膜小胞
Document Type and Number:
Japanese Patent JP3404037
Kind Code:
B2
Abstract:
The phospholipid bi-layer vesicle contains at least one pharmaceutically active drug and comprises cell-specific markers on the membrane which have at least 90 % biological activity when measured according to Luescher & Glueck, Antiviral Research 14, 39-50. In the membrane, the cholesterol content is preferably less than 2% by weight, the detergent content preferably less than 1 ppb. The vesicle diameter preferably is about 80 nm. The phospholipid in the membrane may comprise 70 to 95 % by weight of phosphatidylcholine and preferably 10 to 20 % by weight of phosphatidylethanolamine; preferably 6 to 8 % by weight of a crosslinker, preferably of a sulfosuccinimidyl derivate, and at least one cell-specific fusion peptide are linked to the membrane. The vesicles are used for the preparation of pharmaceuticals against AIDS and carcinomas. The process for the preparation of phospholipid bi-layer vesicles comprises hemagglutinin as a cell-specific marker with at least one fusion peptide. The hemagglutinin is separated from a virus strain by means of a non-ionic detergent, preferably octaethylene glycol monododecyl ether. It is removed by repeatedly treating the solution with altogether about 1.5 g polystyrene beaded microcarriers per 100 mg detergent.
Inventors:
Grueck, Reinhardt
Klein, Peter
Hermann, Peter
Klein, Peter
Hermann, Peter
Application Number:
JP50347192A
Publication Date:
May 06, 2003
Filing Date:
January 17, 1992
Export Citation:
Assignee:
Nika Health Products Limited
International Classes:
A61K9/127; A61K31/16; A61K31/17; A61K31/415; A61K31/505; A61K31/675; A61K31/70; A61K39/395; A61K47/24; A61K47/48; A61P31/18; A61P35/00; (IPC1-7): A61K9/127; A61K31/16; A61K31/17; A61K31/415; A61K31/505; A61K31/675; A61K31/70; A61K39/395; A61K47/24; A61P31/18; A61P35/00
Domestic Patent References:
| JP57118794A | ||||
| JP2502633A | ||||
| JP4506518A |
Attorney, Agent or Firm:
Hideo Takino (2 outside)